标题
Current treatment and recent progress in gastric cancer
作者
关键词
-
出版物
CA-A CANCER JOURNAL FOR CLINICIANS
Volume -, Issue -, Pages -
出版商
Wiley
发表日期
2021-02-20
DOI
10.3322/caac.21657
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Pembrolizumab (pembro) in microsatellite instability-high (MSI-H) advanced gastric/gastroesophageal junction (G/GEJ) cancer by line of therapy.
- (2020) Joseph Chao et al. JOURNAL OF CLINICAL ONCOLOGY
- White blood cell and cell-free DNA analyses for detection of residual disease in gastric cancer
- (2020) Alessandro Leal et al. Nature Communications
- Randomized, Phase II Study of Trastuzumab Beyond Progression in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: WJOG7112G (T-ACT Study)
- (2020) Akitaka Makiyama et al. JOURNAL OF CLINICAL ONCOLOGY
- Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603)
- (2020) Shota Fukuoka et al. JOURNAL OF CLINICAL ONCOLOGY
- Perioperative ramucirumab in combination with FLOT versus FLOT alone for resectable esophagogastric adenocarcinoma (RAMSES/FLOT7): Results of the phase II-portion—A multicenter, randomized phase II/III trial of the German AIO and Italian GOIM.
- (2020) Salah-Eddin Al-Batran et al. JOURNAL OF CLINICAL ONCOLOGY
- The association of tissue tumor mutational burden (tTMB) using the Foundation Medicine genomic platform with efficacy of pembrolizumab versus paclitaxel in patients (pts) with gastric cancer (GC) from KEYNOTE-061.
- (2020) Kohei Shitara et al. JOURNAL OF CLINICAL ONCOLOGY
- Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2-positive resectable esophagogastric adenocarcinoma: Final results of the PETRARCA multicenter randomized phase II trial of the AIO.
- (2020) Ralf Dieter Hofheinz et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab versus paclitaxel for previously treated patients with PD-L1–positive advanced gastric or gastroesophageal junction cancer (GC): Update from the phase III KEYNOTE-061 trial.
- (2020) Charles S. Fuchs et al. JOURNAL OF CLINICAL ONCOLOGY
- First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial
- (2020) Yelena Y Janjigian et al. LANCET ONCOLOGY
- Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer
- (2020) Kohei Shitara et al. NEW ENGLAND JOURNAL OF MEDICINE
- Low metabolic activity in primary gastric adenocarcinoma is associated with resistance to chemoradiation and the presence of signet ring cells
- (2020) Kazuto Harada et al. SURGERY TODAY
- Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial
- (2020) Akihito Kawazoe et al. LANCET ONCOLOGY
- LBA6_PR Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): First results of the CheckMate 649 study
- (2020) M. Moehler et al. ANNALS OF ONCOLOGY
- Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
- (2020) Aurélien Marabelle et al. LANCET ONCOLOGY
- Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer
- (2020) Kohei Shitara et al. JAMA Oncology
- Addition of Docetaxel to Oral Fluoropyrimidine Improves Efficacy in Patients With Stage III Gastric Cancer: Interim Analysis of JACCRO GC-07, a Randomized Controlled Trial
- (2019) Kazuhiro Yoshida et al. JOURNAL OF CLINICAL ONCOLOGY
- Application of positron emission tomography imaging to personalize esophagogastric cancer care
- (2019) Sebastian Mondaca et al. CANCER
- Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy versus palliative systemic chemotherapy in stomach cancer patients with peritoneal dissemination, the study protocol of a multicentre randomised controlled trial (PERISCOPE II)
- (2019) W. J. Koemans et al. BMC CANCER
- Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer With Peritoneal Metastases (CYTO-CHIP study): A Propensity Score Analysis
- (2019) Pierre-Emmanuel Bonnot et al. JOURNAL OF CLINICAL ONCOLOGY
- ARTIST 2: Interim results of a phase III trial involving adjuvant chemotherapy and/or chemoradiotherapy after D2-gastrectomy in stage II/III gastric cancer (GC).
- (2019) Se Hoon Park et al. JOURNAL OF CLINICAL ONCOLOGY
- Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
- (2019) Salah-Eddin Al-Batran et al. LANCET
- A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study
- (2019) O Türeci et al. ANNALS OF ONCOLOGY
- Clinical and molecular predictors of response to immune checkpoint inhibitors in patients with advanced esophagogastric cancer
- (2019) Megan Greally et al. CLINICAL CANCER RESEARCH
- Circulating Tumor DNA Sequencing Analysis of Gastroesophageal Adenocarcinoma
- (2019) Steven B. Maron et al. CLINICAL CANCER RESEARCH
- Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer
- (2019) Filippo Pietrantonio et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
- (2019) Aurelien Marabelle et al. JOURNAL OF CLINICAL ONCOLOGY
- Microsatellite Instability and Programmed Cell Death-Ligand 1 Expression in Stage II/III Gastric Cancer
- (2018) Yoon Young Choi et al. ANNALS OF SURGERY
- Racial disparities in preoperative chemotherapy use in gastric cancer patients in the United States: Analysis of the National Cancer Data Base, 2006-2014
- (2018) Naruhiko Ikoma et al. CANCER
- Oligometastasierung beim Magen- und Ösophaguskarzinom
- (2018) S. Beckert et al. CHIRURG
- Repeat staging laparoscopy for gastric cancer after preoperative therapy
- (2018) Cornelius A. Thiels et al. JOURNAL OF SURGICAL ONCOLOGY
- Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer
- (2018) Seung Tae Kim et al. NATURE MEDICINE
- Targeted Therapies for Targeted Populations: Anti-EGFR Treatment for EGFR -Amplified Gastroesophageal Adenocarcinoma
- (2018) Steven B. Maron et al. Cancer Discovery
- Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300
- (2018) Y -J Bang et al. ANNALS OF ONCOLOGY
- Single agent activity of ZW25, a HER2-targeted bispecific antibody, in heavily pretreated HER2-expressing cancers.
- (2018) Funda Meric-Bernstam et al. JOURNAL OF CLINICAL ONCOLOGY
- CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer
- (2018) Yelena Y. Janjigian et al. JOURNAL OF CLINICAL ONCOLOGY
- Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study
- (2018) Josep Tabernero et al. LANCET ONCOLOGY
- Gastric Cancer Etiology and Management in Asia and the West
- (2018) Ashley E. Russo et al. Annual Review of Medicine
- Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2018) Kohei Shitara et al. LANCET ONCOLOGY
- It Is Time to Stop Using Epirubicin to Treat Any Patient With Gastroesophageal Adenocarcinoma
- (2017) Elena Elimova et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment of localized gastric and gastroesophageal adenocarcinoma: the role of accurate staging and preoperative therapy
- (2017) Brian Badgwell et al. Journal of Hematology & Oncology
- Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study
- (2017) Peter C Thuss-Patience et al. LANCET ONCOLOGY
- Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer
- (2017) Yelena Y. Janjigian et al. Cancer Discovery
- Mismatch Repair Deficiency, Microsatellite Instability, and Survival
- (2017) Elizabeth C. Smyth et al. JAMA Oncology
- Race Is a Risk for Lymph Node Metastasis in Patients With Gastric Cancer
- (2016) Naruhiko Ikoma et al. ANNALS OF SURGICAL ONCOLOGY
- Yield of Staging Laparoscopy and Lavage Cytology for Radiologically Occult Peritoneal Carcinomatosis of Gastric Cancer
- (2016) Naruhiko Ikoma et al. ANNALS OF SURGICAL ONCOLOGY
- Surgery after intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastasis or positive peritoneal cytology findings
- (2016) Hironori Ishigami et al. Gastric Cancer
- Japanese gastric cancer treatment guidelines 2014 (ver. 4)
- (2016) Gastric Cancer
- FAST: An international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without IMAB362, a first-in-class anti-CLDN18.2 antibody, as first-line therapy in patients with advanced CLDN18.2+ gastric and gastroesophageal junction (GEJ) adenocarcinoma.
- (2016) Salah-Eddin Al-Batran et al. JOURNAL OF CLINICAL ONCOLOGY
- Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2–Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC—A Randomized Phase III Trial
- (2016) J. Randolph Hecht et al. JOURNAL OF CLINICAL ONCOLOGY
- Multimodality Therapy of Localized Gastric Adenocarcinoma
- (2016) Brian Badgwell Journal of the National Comprehensive Cancer Network
- Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers
- (2016) Sarah Derks et al. Oncotarget
- Predictors of Survival in Patients with Resectable Gastric Cancer Treated with Preoperative Chemoradiation Therapy and Gastrectomy
- (2015) Brian Badgwell et al. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hereditary Diffuse Gastric Cancer Syndrome
- (2015) Samantha Hansford et al. JAMA Oncology
- GASTRICHIP: D2 resection and hyperthermic intraperitoneal chemotherapy in locally advanced gastric carcinoma: a randomized and multicenter phase III study
- (2014) Olivier Glehen et al. BMC CANCER
- HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer
- (2014) Eric Van Cutsem et al. Gastric Cancer
- Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas
- (2014) Suling J Lin et al. GUT
- Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment ofHER2-Amplified Advanced Gastric Cancer in Asian Populations: TyTAN—A Randomized, Phase III Study
- (2014) Taroh Satoh et al. JOURNAL OF CLINICAL ONCOLOGY
- Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial
- (2014) Susan J Dutton et al. LANCET ONCOLOGY
- Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
- (2014) Hansjochen Wilke et al. LANCET ONCOLOGY
- Comprehensive molecular characterization of gastric adenocarcinoma
- (2014) Adam J. Bass et al. NATURE
- Chemotherapy as palliative treatment for peritoneal carcinomatosis of gastric origin
- (2013) Irene Thomassen et al. ACTA ONCOLOGICA
- Role of chemotherapy for advanced/recurrent gastric cancer: An individual-patient-data meta-analysis
- (2013) EUROPEAN JOURNAL OF CANCER
- Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
- (2013) Charles S Fuchs et al. LANCET
- Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial
- (2013) Florian Lordick et al. LANCET ONCOLOGY
- The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: A randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65+)
- (2012) Salah-Eddin Al-Batran et al. EUROPEAN JOURNAL OF CANCER
- Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial
- (2012) Yung-Jue Bang et al. LANCET
- Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer
- (2012) P. van Hagen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Improves Survival of Patients with Peritoneal Carcinomatosis from Gastric Cancer: Final Results of a Phase III Randomized Clinical Trial
- (2011) Xiao-Jun Yang et al. ANNALS OF SURGICAL ONCOLOGY
- Intensity-modulated radiotherapy combined with chemotherapy for the treatment of gastric cancer patients after standard D1/D2 surgery
- (2011) Changhua Yu et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Five-Year Outcomes of a Randomized Phase III Trial Comparing Adjuvant Chemotherapy With S-1 Versus Surgery Alone in Stage II or III Gastric Cancer
- (2011) Mitsuru Sasako et al. JOURNAL OF CLINICAL ONCOLOGY
- Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial
- (2011) Marc Ychou et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Trial Comparing Capecitabine Plus Cisplatin Versus Capecitabine Plus Cisplatin With Concurrent Capecitabine Radiotherapy in Completely Resected Gastric Cancer With D2 Lymph Node Dissection: The ARTIST Trial
- (2011) Jeeyun Lee et al. JOURNAL OF CLINICAL ONCOLOGY
- Comparison of Gastric Cancer Survival Following R0 Resection in the United States and Korea Using an Internationally Validated Nomogram
- (2010) Vivian E. Strong et al. ANNALS OF SURGERY
- Epirubicin, Oxaliplatin, and Capecitabine With or Without Panitumumab for Advanced Esophagogastric Cancer: Dose-Finding Study for the Prospective Multicenter, Randomized, Phase II/III REAL-3 Trial
- (2010) Alicia F.C. Okines et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
- (2008) David Cunningham et al. NEW ENGLAND JOURNAL OF MEDICINE
- Role of symptoms in diagnosis and outcome of gastric cancer
- (2008) Giovanni Maconi et al. WORLD JOURNAL OF GASTROENTEROLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now